First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

The difference comes from the sourcing of raw materials and the functioning – and even nature – of supply chains. Because the ...

Cell therapy is ... two basic categories: autologous cell therapies, which involve removing a patient’s cells, modifying them, and returning them to the body, and allogeneic cell therapies ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 ...

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.

Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current ...